Moreover, our data are supported by the latest World Health Organization (WHO) Classification of Adrenal Cortical Tumors, which recommends using CYP11B2 immunohistochemistry to identify the functional sites of aldosterone production rather than simply distinguishing functional adenomas from non-functional hyperplasia (34). This evidence concerns the gene CYP11B2 and adrenal cortex carcinoma.